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Interaction between T follicular helper (Tfh) cells and B cells is complex and involves 
various pathways, including the production of IL-21 by the Tfh cells. Secretion of IL-21 
results in B  cell differentiation toward immunoglobulin-producing plasmablasts. In 
patients after kidney transplantation, the formation of alloantibodies produced by donor 
antigen- activated B cells are a major cause of organ failure. In this allogeneic response, 
the role of IL-21-producing Tfh cells that regulate B cell differentiation is unknown. Here, 
we tested, in an alloantigen-driven setting, whether Tfh cell help signals control B cell 
differentiation with its dependency on IL-21. Pre-transplantation patient PBMCs were 
sorted into pure CD4posCXCR5pos Tfh cells and CD19posCD27pos memory B  cells and 
stimulated with donor antigen in the presence or absence of an IL-21 receptor (IL-21R) 
antagonist (αIL-21R). Donor antigen stimulation initiated expression of the activation 
markers inducible co-stimulator (ICOS) and programmed death 1 (PD-1) on Tfh cells and 
a shift toward a mixed Tfh2 and Tfh17 phenotype. The memory B cells underwent class 
switch recombination and differentiated toward IgM- and IgG-producing plasmablasts. 
In the presence of αIL-21R, a dose-dependent inhibition of STAT3 phosphorylation was 
measured in both T and B cells. Blockade of the IL-21R did not have an effect on PD-1 
and ICOS expression on Tfh cells but significantly inhibited B cell differentiation. The 
proportion of plasmablasts decreased by 78% in the presence of αIL-21R. Moreover, 
secreted IgM and IgG2 levels were significantly lower in the presence of αIL-21R. In 
conclusion, our results demonstrate that IL-21 produced by alloantigen-activated Tfh 
cells controls B cell differentiation toward antibody producing plasmablasts. The IL-21R 
might, therefore, be a useful target in organ transplantation to prevent antigen-driven 
immune responses leading to graft failure.
Keywords: alloreactivity, B cell differentiation, plasmablast, il-21 receptor, follicular T-helper cell
Abbreviations: ADA, anti-drug antibodies; ATG, anti-thymocyte globulin; Bcl-6, B-cell lymphoma 6; CSR, class switch 
recombination; CXCR5, C–X–C chemokine receptor 5; DSA, donor-specific antibodies; GC, germinal center; HLA, human 
leukocyte antigen; ICOS, inducible co-stimulator; Ig, immunoglobulin; IL-21R, interleukin 21 receptor; PBMC, peripheral 
blood mononuclear cells; PD-1, programmed death 1; SEB, staphylococcal enterotoxin B; Tfh cell, follicular T helper cell.
TaBle 1 | Patient characteristics at baseline.
study group (n = 17)
Patients age in years (median, range) 57 (33–74)
Recipient gender (% male) 76.5%
HLA-A mismatches (mean ± SD) 1.1 (±0.7)
HLA-B mismatches (mean ± SD) 1.7 (±0.5)
HLA-DR mismatches (mean ± SD) 1.5 (±0.5)
Panel reactive antigen (median, range)
• Current 0.0% (0.0–71%)
• Peak 4.0% (0.0–99%)
Previous kidney transplantation 11.8% (2)
• Second kidney transplantation 5.9% (1)
• Third kidney transplantation 5.9% (1)
Renal replacement therapy before transplantation 88.3% (15)
• Hemodialysis 76.5% (13)
• Peritoneal dialysis 11.8% (2)
Cause of end-stage renal disease
• Hypertensive nephropathy 35.3% (6)
• Diabetic nephropathy 41.2% (7)
• Focal segmental glomerulosclerosis 5.9% (1)
• IgA nephropathy 5.9% (1)
• Polyarteritis nodosa 5.9% (1)
• Unknown 5.9% (1)
Numbers inside the brackets represent patient number unless otherwise specified.
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inTrODUcTiOn
After kidney transplantation, the immunological barrier 
between organ donor and recipient still limits graft survival (1). 
In this setting, a large proportion of allograft recipients develop 
a donor-specific antibody response associated with an increased 
risk for chronic rejection (2–5). This complication accounts for 
more than 50% of chronic transplant failures leading to death, 
dialysis, or re-transplantation of patients (3). Current immuno-
suppressive agents mainly aimed at T-cell-mediated alloimmun-
ity, whereas agents that effectively target humoral effectors are 
still insufficient (6). Therefore, there is a need to develop new 
agents that specifically prevent the activation of B cell-mediated 
immune responses.
Within humoral immunity, T  cell-mediated help to B  cells 
is required for the generation of antigen-specific antibody 
responses. This process is mainly driven via IL-21-secreting T 
follicular helper (Tfh) cells. Tfh cells are well known for their 
expression of CXC chemokine receptor 5 (CXCR5) (7). Sustained 
expression of CXCR5 helps Tfh cells localize to B cell follicles, 
where they interact with germinal center (GC) B cells and pro-
duce IL-21 (8). Through autocrine and paracrine mechanisms, 
IL-21 amplifies and stabilizes Tfh cell-mediated responses, 
B  cell proliferation, immunoglobulin class switch recombina-
tion (CSR), and B cell differentiation toward plasmablasts and 
long-living memory B cells (9, 10). In this respect, IL-21 directly 
effects B cell responses via IL-21 receptor (IL-21R) expressed on 
the B  cells (11, 12). IL-21 signals through a receptor complex 
consisting of IL-21R and a common cytokine receptor γ-chain 
that activates downstream JAK/STAT pathways, predominantly 
by the phosphorylation of STAT3 (13, 14). Transcriptional 
repressor B-cell lymphoma 6 (Bcl-6) orchestrates the differen-
tiation program of Tfh cells, while suppressing other T helper 
subset transcription factors (8, 15). The capacity of Tfh cells to 
interact with B  cells is dependent on T-cell receptor interac-
tion with antigens presented by MHC class II molecules and 
co-stimulatory molecules CD40ligand, inducible co-stimulator 
(ICOS), and programmed death 1 (PD-1) (7, 8). The circulating 
counterparts of the “GC-Tfh cells” in humans express CXCR5, 
low expression levels of PD-1 and ICOS and lack expression of 
transcription repressor Bcl-6 (16–18).
In transplantation, studies on peripheral Tfh cells and their 
role in IL-21 driven B cell differentiation are limited (19, 20). An 
increased frequency of circulating Tfh cells was found in patients 
with chronic antibody-mediated allograft rejection after kidney 
transplantation (21). Furthermore, in patients with pre-existing 
donor-specific antibodies (DSA), an association was detected 
between pre-existing DSAs and the numbers of Tfh cells after 
transplantation (22). Co-stimulation blockade in a non-human 
primate kidney transplant model resulted in reduced IL-21 
production in GC and an attenuated antibody response (23). In 
addition, selective blockade of CD28 solely resulted in lower levels 
of IL-21 compared to CD80/86 co-stimulatory blocking therapy 
(24) For the development of immunosuppressive agents that 
specifically target B  cell-mediated immune responses directed 
toward donor antigen early in the activation cascade, a better 
understanding of Tfh biology is needed.
Kidney disease patients suffer from defective immune 
responses caused by decreased T and B  cell activity (25, 26). 
Therefore, we have used patient materials to set up an in  vitro 
system in which we studied whether Tfh cells instruct donor anti-
gen-driven memory B cells to differentiate into immunoglobulin 
producing plasmablasts. Subsequently, we assessed whether this 
Tfh cell-mediated differentiation and plasmablast formation is 
dependent on IL-21 by blocking the IL-21R with an antagonist 
(αIL-21R). Overall, our data define the role of IL-21/IL-21R 
signaling pathway in alloantigen-driven and Tfh cell-mediated 
B cell differentiation toward Ig-producing plasmablasts.
MaTerials anD MeThODs
study Population
For the in vitro assays, PBMCs of 17 kidney transplant recipients 
obtained 1  day pre-transplantation were analyzed and stimu-
lated with the corresponding kidney donor PBMCs. Patient 
demographics are summarized in Table 1. The Medical Ethical 
Committee of the Erasmus MC, University Medical Center, 
approved this study (MEC-2010-022). All patients and donors 
gave written informed consent. B cell parameters were measured 
in all samples and T  cell assays were performed when enough 
material was available for analysis.
coculture experiments of Peripheral Tfh 
cells and Memory B cells
Coculture experiments with Tfh cells and memory B  cells 
were conducted as schematically represented in Figure S1 in 
Supplementary Material to determine the functional interac-
tions after donor antigen stimulation. PBMCs were thawed and 
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CD3posCD4posCXCR5pos T  cells (Tfh cells) and CD19posCD27pos 
(memory) B  cells were fluorescence activated cell sorted by 
BD-FACSAria II SORP™ (purities ≥96%). Isolated Tfh cells 
(2 × 104 cells/well) were cocultured with memory B cells (2 × 104 
cells/well) in a 96-well plate for 8 days in the presence of irradi-
ated (40  Gy) donor PBMCs (5 ×  104/well). At day 0 and after 
8 days of culture, the Tfh cell phenotype, the B cell phenotype, 
and B  cell differentiation toward Ig-producing plasmablasts 
were measured with flow cytometry. The following monoclonal 
antibodies (MoAbs) were used for the Tfh cell phenotype stain-
ings: CD3 Brilliant Violet 510 (BV510) (Biolegend, San Diego, 
CA, USA), CD4 Brilliant Violet 421 (BV421, Biolegend), CXCR5 
Alexa Fluor 647 (AF647, BD Biosciences, San José, CA, USA), 
ICOS phycoerythrin-Cyanine7 (PE-Cy7, Biolegend), CCR6 PE 
(eBioscience, San Diego, CA, USA), CXCR3 peridinin chlo-
rophyll (PerCP, Biolegend), and PD-1 Allophycocyanin-Cy7 
(APC-Cy7, Biolegend). MoAbs used for the B  cell stainings: 
CD19 BV510 (Biolegend), CD38 BV421 (BD Biosciences), IgG 
APC (BD Biosciences), CD27 Pe-Cy7 (eBioscience), IgM PE (BD 
Biosciences), and IgD APC-Cy7 (Biolegend). 7-aminoactinomy-
cin (7-AAD) PerCP was included to measure cell viability. To 
define the role of IL-21/IL-21R signaling in alloantigen-activated 
Tfh and memory B cells, the cocultures were pre incubated for 
30  minutes with humanized anti-IL-21R antibody ATR-107 
(10 μg/ml, kindly provided by Pfizer, New York, NY, USA) or 
isotype-matched control (10  μg/ml, IgG1-Fc, R&D systems, 
Minneapolis, MN, USA) at 37°C. Hereafter, the irradiated donor 
cells were added to the cocultures and further incubated at 37°C 
for 8 days. Total IgM, IgG, and IgG2 production was measured in 
the culture supernatants with a sandwich ELISA (eBioscience). 
All flow cytometry analyzes were performed with Kaluza Analysis 
1.3 (Beckman Coulter, Fullerton, CA, USA).
Phospho-specific Flow cytometry
Phosphorylation of STAT3 by CD4+ T cells and CD19+ B cells was 
determined by phospho-specific flow cytometry. In brief, PBMCs 
were stained with CD3 BV510 (Biolegend) and CD19 Pe-Cy7 
(Biolegend) for 30  min at RT in the dark. Next, the cells were 
incubated for 30 min at 37°C with various concentrations of the 
humanized anti-IL-21R antibody ATR-107 (Pfizer) or isotype-
matched control (IgG1-Fc, R&D systems) followed by stimula-
tion with recombinant human IL-21 (100 ng/ml, eBioscience) or 
recombinant human IL-6 (100 ng/ml, PeproTech, Rocky Hill, NJ, 
USA) for 15 min at 37°C. Cells were fixed for 10 min with Cytofix 
buffer (BD Biosciences) at 37°C and permeabilized 30 min in 1 ml 
methanol 90% at −20°C. Next, samples were stained with CD4 
BV421 (Biolegend) and pSTAT3 PE (BD Biosciences). STAT3 
phosphorylation was calculated as the median fluorescence 
intensity.
B cell stimulation assay
B  cell stimulation with a minor cocktail of stimuli was per-
formed to study the effect of IL-21, co-stimulation, and BCR 
activation on plasmablast formation. CD19+ B  cells were 
isolated via CD43 negative selection with CD43 MicroBeads 
(Miltenyi Biotec, Bergisch Gladbach, Germany) (purities ≥85%). 
B  cells were incubated with anti-IL-21R antibody ATR-107 
(10 μg/ml, Pfizer) or isotype-matched control (10 μg/ml IgG1-Fc, 
R&D systems). Next, cells were stimulated with 5 μg/ml soluble 
anti-CD40 (Bioceros, Utrecht, The Netherlands), 10 μg/ml goat-
anti-human IgM (Jackson Immunoresearch, West Grove, PA, 
USA) and human recombinant IL-21 (100 ng/ml, eBioscience). 
Subsequently, the presence of plasmablasts on day 0 and the dif-
ferentiation of memory B cells into plasmablasts on day 8 were 
determined with flow cytometry. Plasmablasts were defined as 
CD19posCD27highCD38high cells (16). The following MoAbs were 
used: CD19 BV510 (Biolegend), CD27 Pe-Cy7 (eBioscience), 
IgD APC-Cy7 (Biolegend), and CD38 BV421 (BD Biosciences). 
In addition, viability staining with 7-AAD PerCP was performed 
(BD Biosciences).
statistics
Statistical analyses were performed using Wilcoxon signed-rank 
test and Spearman’s rank correlation test using GraphPad Prism 
5 software (GraphPhad Software, San Diego, CA, USA, http://
www.graphpad.com). A two-tailed p-value < 0.05 was considered 
statistically significant.
resUlTs
Tfh cells are activated upon stimulation 
with alloantigen
We set up an in  vitro system to study the functional interac-
tion of CD4posCXCR5pos Tfh cells and CD19posCD27pos memory 
B cells upon alloantigen stimulation and the role of IL-21 in this 
response. Purified Tfh cells and memory B cells were cocultured 
and stimulated with donor alloantigen. As a negative control, 
donor alloantigen was omitted (Figure S2 in Supplementary 
Material). For gating strategies see Figure  1A. Proportions of 
activation markers PD-1 and ICOS on the Tfh cells significantly 
increased after coculture (Figure  1B, p =  0.02 and p =  0.008, 
respectively).
A heterogeneous Tfh cell population was observed at day 8 
based on expression of chemokine receptors CCR6 and CXCR3. 
Three Tfh subsets can be distinguished: CXCR3posCCR6neg Tfh1 
cells, CXCR3negCCR6neg Tfh2 cells and CXCR3negCCR6pos Tfh17 
cells. Especially the Tfh2 and Tfh17 subsets (CXCR3neg) are able 
to induce B cell differentiation and Ig CSR via IL-21, while the 
CXCR3pos Tfh1 cells lack this capacity (16, 27). The mean pro-
portion of Tfh2 and Tfh17 cells at day 8 after coculture was 71% 
(range: 38–80%), forming the majority of the different subsets 
(Figure 1C).
Tfh-Mediated B cell Differentiation Occurs 
upon stimulation with alloantigen
Over the 8 days of coculture, the composition of surface immu-
noglobulins on the memory B cells changed. After coculture CSR 
toward IgG occurred in part of the samples, with mean propor-
tion surface IgG of 30% (range: 18–56%) before coculture toward 
35% (range: 12–89%) after coculture (Figure 2A, p = 0.04) while 
IgD proportions decreased from mean proportion of 18% (range: 
4–26%) to 7% (range: 0.0–21%) after coculture (Figure  2A, 
p = 0.0009). The proportion of B cells expressing IgM did not 
FigUre 1 | T follicular helper (Tfh) cells are activated upon stimulation with alloantigen. Tfh cells and memory B cells from patients, pre kidney 
transplantation, were stimulated with alloantigen and cocultured for 8 days. (a) Typical example of Fluorescence activated cell sorting gating strategy to obtain 
CD4posCXCR5pos Tfh cells and CD19posCD27pos memory B-cells. Cells were gated from viable (7-AAD negative) lymphocytes, defined by forward- and side-scatter. 
(B) Histogram overlays and quantified data of proportions programmed death 1 (PD-1) and inducible co-stimulator (ICOS) within CD4posCXCR5pos Tfh cells at 
baseline (day 0) and day 8 after coculture (PD-1 n = 7; ICOS n = 8). (c) Gating strategy and distribution of proportions CCR6negCXCR3pos Tfh1, CCR6negCXCR3neg 
Tfh2 and CCR6posCXCR3neg Tfh17 cells of the total Tfh population on day 0 and 8 after coculture. N.B.: box whiskers represent minimal and maximal values. The 
upper and lower borders of the box represent the 25 and 75% percentile, respectively, with the middle line representing the median (n = 8).
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FigUre 2 | T follicular helper (Tfh)-mediated B cell differentiation occurs upon stimulation with alloantigen. Tfh and memory B cells were stimulated with 
alloantigen and cocultured for 8 days. (a) Gating strategy of surface immunoglobulins IgM, IgD, and IgG within the memory B cell population before and after 
coculture and corresponding quantified data (n = 17). (B) Gating strategy of CD27highCD38high plasmablasts and remaining memory B cells at baseline (day 0) and 
after 8 days coculture is depicted on the left. Quantified data of plasmablast proportions at day 0 and after 8 days coculture are depicted on the right. Dashed line 
distinguishes between cultures with a high plasmablast proportion (>10%) compared to a low plasmablast proportion (<5%) at day 8 (n = 17). (c) Correlation 
between proportion of plasmablasts and IgM or IgG (ng/ml) in the culture supernatant after 8 days coculture (n = 16) (*p < 0.05, **p < 0.003, ***p < 0.0009). Pb, 
plasmablast.
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significantly change after the coculture (Figure 2A, p = 0.09). A 
significant increase in plasmablast numbers was observed after 
coculture, proving the robust capacity of alloantigen and Tfh cells 
in stimulating memory B  cell differentiation (Maximum 28%, 
Figure 2B, p = 0.003). This increase in plasmablast numbers was 
not observed in cocultures without donor alloantigen stimula-
tion (Figure S2 in Supplementary Material). Based on the median 
proportion (10%) at day 8, we observed a group of cultures 
with high plasmablast proportions (> 10%, n = 9) and a group 
with low plasmablast proportions after culture (<  5%, n =  8). 
No significant differences were found between the two groups 
based on baseline characteristics (Table S1 in Supplementary 
Material). The immunoglobulin producing capacity of the gen-
erated plasmablasts was proven by the correlation between the 
proportion of plasmablasts and the concentration of IgM or IgG 
in the supernatants of all cultures (Figure 2C, p < 0.0001 and 
p = 0.0006, respectively). Overall, we showed that kidney trans-
plant patient-derived circulating Tfh cells before transplantation 
can be activated and are capable to stimulate memory B  cell 
CSR and differentiation toward plasmablasts in the presence of 
alloantigen.
Phosphorylation of sTaT3 is inhibited in 
the Presence of αil-21r antibodies
To determine the functionality of the IL-21R antibody (αIL-21R) 
in blocking IL-21R induced signaling events in T and B cells, we 
performed phospho-specific flow cytometry. Phosphorylation 
of STAT3 was measured after stimulation with IL-21 or IL-6 
(positive control). The specificity of αIL-21R was demonstrated 
by a 3.5-fold reduction in the phosphorylation of STAT3 on 
CD4+ T cells in the presence of 2 μg/ml αIL-21R onward when 
comparing the IL-21 stimulated cells with the IL-6 stimulated 
cells (Figure 3A). Complete inhibition of STAT3 phosphoryla-
tion in the presence of αIL-21R was seen on both T and B cells 
(Figures 3B,C, p =  0.002 and p =  0.0005, respectively). In the 
presence of an isotype-matched control of αIL-21R the STAT3p 
levels were similar to the condition with only IL-21 stimulation. 
From these findings we conclude that αIL-21R efficiently blocks 
IL-21R induced signaling in T and B cells.
αil-21r inhibits Memory B cell 
Differentiation upon alloantigen 
stimulation
To explore the importance of the IL-21/IL-21R signaling pathway 
in an allogeneic system, αIL-21R was added to the cocultures 
containing Tfh cells and memory B cells stimulated with alloan-
tigen. Both cell populations expressed IL-21R (Figure S3 in 
Supplementary Material). Prior to the cocultures, we tested the 
capacity of αIL-21R to block the formation of plasmablasts in a 
culture system described by Ettinger and colleagues, where B cells 
were stimulated with anti-CD40, anti-IgM and IL-21 resulting 
in robust plasmablast proportions (28). Significant inhibition of 
plasmablast formation was found in the presence of αIL-21R in 
this setting (Figure S4 in Supplementary Material).
Next, we tested the efficacy of αIL-21R to block in our alloan-
tigen Tfh–B cell coculture system. To determine the inhibitory 
capacity of αIL-21R on B cell function, we focused on the cultures 
with the highest proportion of plasmablasts. Cultures with low 
plasmablast proportions (<5%) were excluded. In these samples, 
after the culture period of 8  days, no differences were found 
regarding the phenotype of the Tfh cells. Moreover, proportions of 
PD-1, ICOS, and the distribution of CCR6 and CXCR3 expressed 
were comparable in the presence and absence of αIL-21R (Figure 
S5 in Supplementary Material). Thus, activated Tfh cells and their 
Tfh1, Tfh2, or Tfh17 phenotype are not altered in terms of their 
phenotype when cultured with αIL-21R.
In the presence of αIL-21R, formation of plasmablasts 
was inhibited by 78% (p =  0.004, Figure 4A). In parallel, IgM 
production was inhibited from mean production of 169 ng/ml 
(range: 20–226 ng/ml) to 38 ng/ml (range: 2–50 ng/ml) in the 
presence of αIL-21R (p = 0.004, Figure 4B). Since αIL-21R is a 
fully humanized IgG1 compound, we measured IgG2 levels in 
the culture supernatant. Although IgG2 is a non-complement-
fixing antibody, the IgG2 subclass of antibodies is the second 
most common Ig subclass present after immunization (29). 
Production of IgG2 decreased from mean production of 975 ng/
ml (range: 116–6763 ng/ml) to 87 ng/ml (range: 22–540 ng/ml) in 
the presence of αIL-21R (p = 0.004, Figure 4B). Taken together, 
these data show that the αIL-21R antibody has the capacity to 
inhibit B  cell differentiation and subsequent immunoglobulin 
production.
DiscUssiOn
We studied the activation of Tfh and memory B  cells upon 
stimulation with alloantigen and the role of IL-21 within this 
process. The present study demonstrates that stimulation of Tfh 
and memory B  cells with donor alloantigen results in an acti-
vated Tfh2 and Tfh17 phenotype, CSR of memory B cells, and 
differentiation of antigen-driven memory B  cells toward IgM 
and IgG producing plasmablasts. In the presence of αIL-21R, 
formation of plasmablasts and IgM and IgG2 production were 
significantly inhibited. Our in vitro system is of high value to test 
other interventions that might alter Tfh-B cell interaction after 
alloantigen response.
While αIL-21R nicely inhibited IL-21 dependent STAT3p, the 
Tfh cell phenotype was not changed (Figure S5 in Supplementary 
Material). This suggests that the autocrine effect of IL-21 on the 
Tfh cell and the presence of antigen is not essential for upregula-
tion of activation markers PD-1, ICOS, and chemokine receptors 
CCR6 and CXCR3. Our data are in line with in vivo and in vitro 
studies where the absence of either IL-21 or IL-6 did not affect 
Tfh differentiation, whereas combined absence of IL-21 and IL-6 
led to a decreased Tfh frequency and Bcl6 gene expression (15, 
30, 31). Thus, in our coculture system, the effect of IL-21 on the 
Tfh cell phenotype is redundant.
In our patient cohort, a high inter-individual variation in 
plasmablast numbers was observed after 8 days stimulation of Tfh 
and memory B cells with donor antigen (Figure 2B) reflecting the 
natural variation among patients. Response toward alloantigen 
apparently varied among the different cocultures, even though 
no significant differences in baseline characteristics were found 
between the cocultures with and without plasmablast formation 
FigUre 3 | Phosphorylation of sTaT3 is inhibited in the presence of αil-21r antibodies. (a–c) PBMCs were stimulated with 100 ng/ml IL-21 or 100 ng/ml 
IL-6 for 15 min in the absence or presence of 10 μg/ml αIL-21R or 10 μg/ml IgG1 isotype. median fluorescence intensity (MFI) values of phosphorylated STAT3 were 
measured directly afterward. (a) Dose–response curve of STAT3p in CD4pos T cells stimulated with 100 ng/ml IL-21 and different concentrations of αIL-21R. 
Stimulation with 100 ng/ml IL-6 was used as a positive control. (B–c) Histogram overlays and quantified data of phosphorylated STAT3 MFI values in CD4pos T-cells 
(B) and CD19pos B-cells (c) (n = 7) (*p < 0.05, **p < 0.005, ***p < 0.0005). Upper line of the boxes represent mean with SEM represented by the whiskers.
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(Table S1 in Supplementary Material). Immunological variation, 
e.g., distinct expression rates of co-stimulation surface markers 
or distinct IL-21 production by the Tfh cells among the differ-
ent cocultures might contribute to this variation. Finally, effect 
of vaccination or viral infection might support the formation 
of alloantibody-producing plasmablasts via cross-reactivity. 
This cross-reactivity results in heterologous immunity within 
the patient population, this may contribute to the variation in 
plasmablast numbers in our cocultures (32).
In transplantation, the formation of complement fixing DSA 
and anti-HLA antibodies is associated with graft loss (2–5). In 
the presence of currently prescribed immunosuppressive drugs, 
de novo DSA and anti-HLA antibodies can be formed which 
contribute to the process of allograft rejection leading to graft loss 
(4, 33). A first hint that IL-21-producing Tfh cells are involved in 
processes leading to the production of alloantibodies comes from 
our study reporting that the absolute numbers of Tfh cells after 
transplantation are the highest in patients with pre-existing DSA 
(22). In addition, this study reports a decrease in plasmablast 
numbers when stimulating Tfh and memory B cells with staphy-
lococcal enterotoxin B, a strong polyclonal superantigen (22). In 
the present study, we determined the mechanisms involved by 
analyzing the IL-21+ Tfh and B  cell activation pathway during 
activation by donor antigen solely. This study demonstrates that 
alloantigen and IL-21 are key factors in this response. Translating 
the outcome of our in vitro study by using patient materials, we 
speculate that also in vivo B cell differentiation might be medi-
ated by IL-21-producing Tfh cells and that interaction with donor 
antigen stimulated B cells results in the formation of DSA. Future 
experiments, e.g., in  vivo experimental transplantation studies, 
FigUre 4 | αil-21r inhibits memory B cell differentiation upon alloantigen stimulation. CD4posCXCR5pos Tfh-cells and CD19posCD27pos memory B-cells 
stimulated with alloantigen were cocultured for 8 days in the presence or absence of 10 μg/ml αIL-21R. Only the cultures with >10% plasmablasts at day 8 (high 
responders) are depicted. (a) Representative dotplots and quantified data of proportions CD27highCD38high plasmablasts at day 8 after coculture in the presence or 
absence of αIL-21R. (B) Total IgM and IgG2 measured in supernatants after 8 days coculture (n = 9) (**p < 0.004). y-axes for Ig production are scaled log-linearly.
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should reveal whether indeed IL-21 drives antibody-mediated 
allogeneic immune responses.
In a phase I trial in healthy volunteers, 76% of the participants 
who received αIL-21R developed anti-drug antibodies due 
to increased activity of the antigen presentation machinery 
(34, 35). Thus, identification of an IL-21R blocker with lower 
immunogenicity or a switch to an IL-21 cytokine antagonist 
may be an alternative. In addition, in sensitized patients αIL-21R 
may not work sufficiently since these patients have high levels 
of circulating DSA due to previous transplants or pregnancy. 
In these patients, the destructive effects of the existing plasma 
cells need to be neutralized, for instance via protease inhibitors, 
inhibition of IL-6, or inhibition of BAFF and APRIL (6). To date, 
B-cell depletion is achieved via treatment with the anti-CD52 
antibody alemtuzumab, anti-thymocyte globulin (ATG), and 
anti-CD20 antibody rituximab. Compared to these treatments, 
IL-21R blocking therapy is of interest since it is a biological that 
mainly interferes with the Tfh-B cell crosstalk, saving the pres-
ence of T and B cells with a resting or regulatory phenotype. The 
use of anti-IL6R treatment to decrease the formation of anti-HLA 
antibodies has also been widely studied. The first study in kidney 
transplant patients and experimental transplant models showed 
that anti-IL6R treatment affected the proportion Tfh cells and 
reduced B cell differentiation toward IgG-producing plasmablasts 
(36–38). In these studies, no data were reported on anti-IL21R 
agents and a next step would be to compare the functionality of 
these biologicals. We speculate that inhibition of both pathways, 
i.e., IL-6 and IL-21, may be of interest to test.
In this study, we focused on the interplay between peripheral 
Tfh cells and B  cells. Low numbers of IL-21 producing T  cells 
are present in the circulation, compared to high numbers found 
in inflamed tissues (39). In transplantation, the presence of Tfh 
cells that co-localized with B cells in follicular-like structures was 
confirmed in kidney biopsies taken during acute cellular rejec-
tion, suggesting IL-21-mediated Tfh–B  cell interaction in local 
tertiary lymphoid structures in the kidney allograft (22, 23). In 
depth analysis of these graft infiltrating Tfh and B cells, e.g., via 
next generation sequencing or other single cell analysis, would be 
of great importance to improve our knowledge about molecular 
pathways involved in the anti-donor response.
Identifying the mode of action of Tfh-mediated activation 
of B  cells upon alloantigen stimulation is important to further 
understand immunological processes that occur in transplant 
patients. In our allogeneic coculture system, IL-21 plays a non-
redundant role in promoting B cell differentiation, as blockade of 
the IL-21/IL-21R signaling pathway resulted in almost complete 
inhibition of plasmablast formation as well as antibody produc-
tion. In conclusion, our results demonstrate that IL-21 produced 
by alloantigen activated Tfh cells controls B cell differentiation 
toward antibody producing plasmablasts. The IL-21R might, 
therefore, be a useful target in organ transplantation to prevent 
rejection.
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